Kornitzer Capital Management Inc. KS Has $11.30 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Kornitzer Capital Management Inc. KS cut its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 17.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 75,006 shares of the company’s stock after selling 16,285 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in TransMedics Group were worth $11,297,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of TransMedics Group by 10.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after purchasing an additional 38,951 shares during the period. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares during the period. Alpha DNA Investment Management LLC bought a new stake in TransMedics Group in the 4th quarter valued at about $500,000. Russell Investments Group Ltd. boosted its holdings in TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after acquiring an additional 26,997 shares in the last quarter. Finally, Hsbc Holdings PLC grew its stake in TransMedics Group by 19.0% in the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock valued at $3,287,000 after acquiring an additional 6,650 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on TMDX shares. TD Cowen increased their target price on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Needham & Company LLC began coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Stephens boosted their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Oppenheimer raised their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.44.

Insider Activity

In related news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now directly owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock worth $9,551,089 in the last three months. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

TMDX stock traded down $7.33 during midday trading on Thursday, reaching $143.65. 805,683 shares of the company’s stock traded hands, compared to its average volume of 760,676. The company has a 50-day moving average price of $155.12 and a two-hundred day moving average price of $123.84. The firm has a market capitalization of $4.73 billion, a PE ratio of -417.65 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. During the same period last year, the business earned ($0.03) earnings per share. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1.2 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.